Genmab — Marts 2025

[E_L]

Genmab
@Genmab
Our work is personal – we hope to help advance cancer treatment and provide better outcomes for patients. In this edition of #AntibodyHour
, Leslie Amendola, SVP, US General Manager, shares her experience with losing her mother to cancer and her role as a care partner. https://x.com/Genmab/status/1902360084237214004

[lahn1]

Vi krydser fingre for gode OS data fra MARIPOSA. Ved vi hvornår vi forventer Paloma-3 data og ved vi hvordan den regulatriske vej for SC vil være inden den kan lanceres sammen med lazertinib ???

[E_L]

ELCC 2025 - Conference Calendar -Found 8 Presentations For Request "Amivantamab" - https://cslide.ctimeetingtech.com/coasis_21204/attendee/confcal/presentation/list?q=Amivantamab

[E_L]

acasunlimab Trial design - 128TiP - ABBIL1TY NSCLC-06: A global, randomized, open-label, phase III trial of acasunlimab in combination with pembrolizumab (Pembro) vs docetaxel in checkpoint inhibitor (CPI)-experienced patients with PD-L1+ metastatic non-small cell lung cancer (mNSCLC) https://cslide.ctimeetingtech.com/coasis_21204/attendee/confcal/presentation/list?q=acasunlimab+#presentation-abstract-356715098915

[E_L]

presentation: Congress:
SGO 2025
Product:
Rinatabart Sesutecan https://www.genmabmedicalaffairs.com/congress?filv1=22

[E_L]

Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report https://www.sciencedirect.com/science/article/abs/pii/S0165572825000700

[lahn1]

Haha thx EL ! looks great. While the median has not yet been reached for ami+laz, it is expected to provide an OS benefit of at least 12 mo

[lahn1]

SC vs IV data ser også gode ud. Ami+Laz ligner en ny SOC i 1L.

[lahn1]

Er der sammenlignlige OS data på osi+ct ??

[Solsen]

https://www.oncnursingnews.com/view/adding-chemo-to-osimertinib-improves-survival-after-progression-in-egfr-mutant-nsclc Mn denne kan bruges

[E_L]

RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025 https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-significantly-outperforms-standard-of-care-in-first-line-egfr-mutated-lung-cancer-with-compelling-new-data-at-elcc-2025

[Solsen]

Det ligner noget rigtigt godt. Måske de $5bn holder for Amivantamab.

[Solsen]

Jeg tror SB skal fremrykke omsætningen i hans regneark på Rybrevent

[Solsen]

Tagrisso omsatte for $6,5 bn sidste hos Astrazeneca.

[Solsen]

Ærgerlig vi kun er få tilbage der kan glædes over gode resultater

[Plimsoller]

Ved vi noget om status på tilbagekøbsprogrammet?

[Solsen]

Tak Helge. De tidlige Rina-S data giver mulighed for, at vi i sidste ende vil kunne se 15-25% CR i PROC pts. Uhørt i en second line solid cancer og i ovarie cancer i særdeleshed.

[lahn1]

Solsen tror ik det er det rigtige sammenlignings grundlng. Det er 2L. Har prøvet at finde data på FLAURA2 men der er ik OS på nuværende tidspunkt. Men den kombi ser generelt stærk ud , men med chemo kommer der også AEs på niveau eller mere end Ami+Laz.

[Solsen]

Netop de lancere kombinationen som kemofri

[Solsen]

Er det ikke data fra FLAURA2 ?